This month of May is ALS Awareness Month, and marks an opportune time to spotlight the disease and the importance of ...

Late last year, the therapy developers dosed their first patient following positive preclinical data demonstrating safety and ...

Spinogenix has received clearance from the U.S. Food and Drug Administration (FDA) to launch an expanded access program (EAP) ...

Dr. Gomez brings extensive neuroscience and orphan disease development experience to Raya as it plans multiple clinical trials in 2026. MONTREAL, QUEBEC, CANADA, May 8, 2025 /EINPresswire.com/ -- Raya ...

Within a couple hours, the bride was doing the limbo under Eby’s walker, and Eby was giving people walker rides all over the ...

Golden said painless progressive weakness is the key to recognizing ALS, and although research still has a long way to go, ...

Coya Therapeutics, Inc.’s COYA share price has surged by 12.31%, which has investors questioning if this is right time to ...

The third patient of Elon Musk's brain computer interface company Neuralink is using the billionaire's foul-mouthed AI ...

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S.

Clene’s cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be ...

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.